774213-79-5

Upstream product

• 494799-19-8 methyl 2-bromo-3-cyclohexyl-1H-indole-6-carboxylate 
• 5292-43-3 bromoacetic acid tert-butyl ester 
• 108-94-1 cyclohexanone 
• 50820-65-0 indole-6-carboxylic acid methyl ester 
• 494799-16-5 3-(cyclohex-1-en-1-yl)-1H-indole-6-carboxylic acid 
• 494799-17-6 3-cyclohexyl-1-methyl-1H-indole-6-carboxylic acid 
• 494799-18-7 methyl 3-cyclohexyl-1H-indole-6-carboxylate 

Downstream Products

• 886042-36-0 methyl 1-(2-tert-butoxy-2-oxoethyl)-3-cyclohexyl-2-(2-formyl-3-thienyl)-1H-indole-6-carboxylate 
• 886041-22-1 methyl 1-(2-tert-butoxy-2-oxoethyl)-3-cyclohexyl-2-(2-formylphenyl)-1H-indole-6-carboxylate 
• 774213-84-2 methyl 1-(2-tert-butoxy-2-oxoethyl)-3-cyclohexyl-2-phenyl-1H-indole-6-carboxylate 
• 877273-36-4 methyl 2-{2-[(tert-butoxycarbonyl)amino]phenyl}-1-(2-tert-butoxy-2-oxoethyl)-3-cyclohexyl-1H-indole-6-carboxylate 
• 1422252-09-2 C₃₃H₃₅FN₂O₅ 
• 1422252-13-8 C₂₈H₃₁ClFNO₄ 
• 1422252-15-0 C₃₄H₃₇NO₅ 
• 1429320-27-3 C₃₂H₃₉ClFN₃O₄ 
• 494799-84-7 [3-cyclohexyl-2-(3-furyl)-6-(methoxycarbonyl)-1H-indol-1-yl]acetic acid 
• 1422251-87-3 C₄₂H₅₄N₄O₅S 
• 1422251-88-4 C₄₁H₅₀N₄O₅S 
• 1422251-90-8 C₄₀H₅₁N₅O₅S 
• 1422251-98-6 C₃₉H₄₉FN₆O₅S 
• 1422251-93-1 C₃₈H₄₇N₅O₅S*C₂HF₃O₂ 

Relevant academic research and scientific papers

Allosteric N-acetamide-indole-6-carboxylic acid thumb pocket 1 inhibitors of hepatitis C virus NS5B polymerase-Acylsulfonamides and acylsulfamides as carboxylic acid replacements

Acylsulfonamide and acylsulfamide as surrogates for the carboxylic acid function of N-acetamide-indole-6-carboxylic acids were evaluated as allosteric inhibitors of hepatitis C virus (HCV) NS5B polymerase. Several analogs displayed excellent antiviral pot

Syntheses and initial evaluation of a series of indolo-fused heterocyclic inhibitors of the polymerase enzyme (NS5B) of the hepatitis C virus

Herein, we present initial SAR studies on a series of bridged 2-arylindole-based NS5B inhibitors. The introduction of bridging elements between the indole N1 and the ortho-position of the 2-aryl moiety resulted in conformationally constrained heterocycles

AROMATIC HETEROCYCLIC FUSED INDOLOBENZADIAZEPINE HCV NS5B INHIBITORS

The disclosure provides compounds of formula (I), including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.

Antiviral indoles

Compounds of the formula (I): wherein A, B, D, M, Ar, W, X, Y, Z and R1 are as defined herein, are useful in the prevention and treatment of hepatitis C infections. The compounds, their preparation, pharmaceutical compositions containing them and their use in medicine are disclosed.

TETRACYCLIC INDOLE DERIVATIVES AS ANTIVIRAL AGENTS

The present invention relates to tetracyclic indole derivatives of formula (I): wherein Ar, A, R1, R2, L, W, X, Y and Z are defined herein, and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising them, a

Inhibitors of HCV replication

Indole compounds of Formula I are described. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV. Different forms and compositions comprising the compounds are also described as well as methods of preparing the compounds.

INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS

Disclosed are compounds having formula I and related compositions and methods thereof. The compounds are useful for treating viral infections caused by the Flaviviridae family of viruses.

TETRACYCLIC INDOLE DERIVATIVES AS ANTIVIRAL AGENTS

The present invention relates to tetracyclic indole compounds of formula (I); wherein R1, R2, A, Ar, W, X, Y and Z are defined herein, and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising them, and their use for the treatment or prevention of infection by hepatitis C virus.

INDOLE DERIVATIVES AS ANTIVIRAL AGENTS

The present invention relates to indole compounds of the formula (I): wherein R1, R2, R3, R4, A, E and X are as defined herein, and pharmaceutically acceptable salts thereof, useful in the prevention and treatment of hepatitis C infections.

Development and preliminary optimization of indole-N-acetamide inhibitors of hepatitis C virus NS5B polymerase

Allosteric inhibition of the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase enzyme has recently emerged as a viable strategy toward blocking replication of viral RNA in cell-based systems. We report here a novel class of allosteric inhibitor of NS5B that shows potent affinity for the NS5B enzyme and effective inhibition of subgenomic HCV RNA replication in HUH-7 cells. Inhibitors from this class have promising characteristics for further development as anti-HCV agents.